Market research
LRMR Larimar Therapeutics Inc
NASDAQ USD Healthcare
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 434M
- P/E ratio
- Not available
- Analyst target
- 14.3
- Dividend yield
- Not available
- Beta
- 0.75
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US5171251003
- Market cap
- 434M
- P/E ratio
- Not available
- Analyst target
- 14.3
- Dividend yield
- Not available
- Beta
- 0.75
About
About Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the LRMR discussion.
5 years, 4 months ago
Larimar Therapeutics, Inc is currently in a long term downtrend where the price is trading 33.5% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Larimar Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 95.9% to $-14M since the same quarter in the previous year.
Finally, its free cash flow grew by 2.3% to $-10M since the same quarter in the previous year.
Based on the above factors, Larimar Therapeutics, Inc gets an overall score of 2/5.